Deferred Grant Funding, Current

No definition available.

Name:	dare_DeferredGrantFundingCurrent
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Non-Dilutive Grant Funding, Percentage Excluded

+ References

No definition available.

+ Details

Name:	dare_NonDilutiveGrantFundingPercentageExcluded
Namespace Prefix:	dare_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Proceeds From Award Of Grants

+ References

No definition available.

+ Details

Name:	dare_ProceedsFromAwardOfGrants
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Proceeds From Research and Development Arrangement with Federal Government

+ References

No definition available.

+ Details

Name:	dare_ProceedsFromResearchAndDevelopmentArrangementWithFederalGovernment
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Receivable For Expenses Eligible For Reimbursement

+ References

No definition available.

+ Details

Name:	dare_ReceivableForExpensesEligibleForReimbursement
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Research And Development Arrangement, Performance Period

+ References

No definition available.

+ Details

Name:	dare_ResearchAndDevelopmentArrangementPerformancePeriod
Namespace Prefix:	dare_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred, For General And Administrative Expenses, Percentage

+ References

No definition available.

+ Details

Name:	dare_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurredForGeneralAndAdministrativeExpensesPercentage
Namespace Prefix:	dare_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 310
-SubTopic 20
-Name Accounting Standards Codification
-Section 40
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481628/310-20-40-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-2

+ Details

Name:	us-gaap_AccountsNotesAndLoansReceivableLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_GrantsReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12A
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

+ Details

Name:	us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dare_DAREHPVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dare_GrantDAREPTB1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_PhaseIISegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dare_DARELARC1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dare_NICHDMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dare_GrantDAREPTB2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dare_ContraceptiveProductGrantAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dare_BiotherapeuticProductGrantAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dare_DARELBTMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=dare_FoundationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=dare_NationalCollegiateInventorsAndInnovatorsAllianceInc.DbaVentureWellMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dare_FederalSubawardMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Grant Awards (Details) - USD ($)		1 Months Ended					12 Months Ended		43 Months Ended
Grant Awards (Details) - USD ($)	Nov. 11, 2024	Nov. 30, 2025	Dec. 31, 2024	Oct. 31, 2024	Dec. 31, 2023	Jul. 31, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2024	Nov. 30, 2024	Jul. 31, 2024	Jan. 31, 2024	Nov. 30, 2022	Jun. 30, 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]
Deferred grant funding			$ 16,561,625				$ 19,651,452	$ 16,561,625	$ 16,561,625
Research and development							5,523,352	14,305,208
Minimum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Non-dilutive grant funding, percentage excluded												5.00%
Maximum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Non-dilutive grant funding, percentage excluded												15.00%
DARE-HPV
Accounts, Notes, Loans and Financing Receivable [Line Items]
Amount awarded for grant			1,000,000.0
Credits recorded to research and development expense for costs related to award							700,000	0
Receivable for expenses eligible for reimbursement							11,000
Grant, DARE-PTB1 \| Phase II Segment
Accounts, Notes, Loans and Financing Receivable [Line Items]
Amount awarded for grant					$ 2,000,000.0
Credits recorded to research and development expense for costs related to award							700,000	700,000
Receivable for expenses eligible for reimbursement			84,000				0	84,000	84,000
DARE-LARC1
Accounts, Notes, Loans and Financing Receivable [Line Items]
Amount awarded for grant									41,800,000
Deferred grant funding			10,800,000				12,600,000	10,800,000	10,800,000
Initial payment														$ 49,000,000.0
Research and development							8,200,000	6,200,000
NICHD
Accounts, Notes, Loans and Financing Receivable [Line Items]
Amount awarded for grant						$ 400,000
Grant, DARE-PTB2
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivable for expenses eligible for reimbursement											$ 400,000
Contraceptive Product Grant Agreement
Accounts, Notes, Loans and Financing Receivable [Line Items]
Credits recorded to research and development expense for costs related to award							3,700,000	200,000
Deferred grant funding			5,200,000				5,100,000	5,200,000	5,200,000
Biotherapeutic Product Grant Agreement
Accounts, Notes, Loans and Financing Receivable [Line Items]
Credits recorded to research and development expense for costs related to award								700,000
Initial payment												$ 750,000
DARE-LBT
Accounts, Notes, Loans and Financing Receivable [Line Items]
Initial payment													$ 585,000
Research and development expense credit								200,000
Foundation \| Contraceptive Product Grant Agreement
Accounts, Notes, Loans and Financing Receivable [Line Items]
Amount awarded for grant	$ 5,400,000	$ 3,600,000
Initial payment										$ 10,700,000
National Collegiate Inventors And Innovators Alliance, Inc. d/b/a VentureWell \| Federal Subaward
Accounts, Notes, Loans and Financing Receivable [Line Items]
Amount awarded for grant				$ 10,000,000.0
Performance period				24 months
Research and development funding percentage				22.00%
Proceeds from research and development arrangement with federal government							5,500,000
Credits recorded to research and development expense for costs related to award							3,100,000	400,000
Deferred grant funding			$ 600,000				$ 2,000,000.0	$ 600,000	$ 600,000